VIDEO: Speaker reviews pros, cons of combining targeted therapy, immunotherapy for melanoma

Source: Healio, April 2017

NEW YORK — Jason J. Luke, MD, FACP, assistant professor of medicine at University of Chicago, spoke at HemOnc Today Melanoma and Cutaneous Malignancies about the use of targeted therapy in combination with immunotherapy for the treatment of melanoma.

He provided an overview of multiple phase 3 clinical trials designed to evaluate the use of BRAF or MEK inhibitors with PD-1 antibodies. Those trials are assessing various combinations and sequencing approaches.

“I do have to challenge, however, whether continuous dosing is the right idea. There is mounting evidence that suggests mechanisms of resistance are overlapping between BRAF targeted therapy and immunotherapy, and that may, in fact, limit the relative increase we see with triplets,” Luke said.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories